Powder for infusion 25mg, 100mg
First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.
Indolent non-Hodgkin’s lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.
Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment.
Powder for solution for injection 15,000IU indicated for the treatment of
Solution for infusion 20mg/1ml, 80mg/4ml, 140mg/7ml
Taxceus (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:
Taxceus is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.
Taxceus in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.
Taxceus in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.
Taxceus in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
Taxceus in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
Concentrate for solution for infusion 50mg, 150mg, 450mg indicated for the treatment of
Solution for infusion 10mg/5ml, 50mg/25ml, 200mg/100ml
Doxorubicin is a cytotoxic medicinal product that is indicated in the following neoplastic conditions:
Small-cell lung cancer (SCLC), Breast cancer, Recurrent ovarian carcinoma, Systemic treatment of local advanced or metastasized bladder carcinoma, Intravesical prophylaxis of recurrences of superficial bladder carcinoma following transurethral resection, Neoadjuvant and adjuvant therapy of osteosarcoma, Advanced soft-tissue sarcoma in adults, Ewing’s sarcoma, Hodgkin’s disease, Non-Hodgkin’s lymphoma, Acute lymphatic leukaemia, Acute myeloblastic leukaemia, Advanced multiple myeloma, Advanced or recurrent endometrial carcinoma.
Solution for injection 10mg/5ml, 50mg/25ml, 200mg/100ml
Epirubicin is used in the treatment of a range of neoplastic conditions including:
When administered intravesically, epirubicin has been shown to be beneficial in the treatment of:
Solution for infusion 100mg/5ml, 500mg/25ml
Etoposide is indicated for the management of:
Solution for injection
25mg/ml – 2500mg/100ml
50mg/ml – 500mg/10ml, 1000mg/20ml, 2500mg/50ml, 500mg/100ml
Fluorouracil Injection, 25mg/ml and 50 mg/ml solution for injection, may be used alone or in combination, for its palliative action in the management of common malignancies particularly cancer of the colon and breast, either as single agent or in combination with other cytotoxic agents.
Powder for solution for infusion 38 mg/ml. 200mg, 1000mg, 1500mg
Gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin.
Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.
Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2.
Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy.
Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.
Solution for infusion 40mg/2ml, 100mg/5ml, 300mg/15ml
Irinotecan medac is indicated for the treatment of patients with advanced colorectal cancer
Irinotecan medac in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy.
Irinotecan medac in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.
Solution for infusion 50mg, 100mg, 200mg
Oxaliplatin medac is used in combination with 5-fluorouracil (5-FU) and folinic acid (FA) for:
Solution for infusion 30mg/5ml, 100mg/16.7ml, 300mg/50ml
For first-line treatment of carcinoma of the ovary, paclitaxel is indicated in combination with cisplatin in patients with advanced disease or a residual tumour (> 1 cm) following laparotomy.
For second-line treatment of carcinoma of the ovary, paclitaxel is indicated for treatment of metastatic carcinoma of the ovary after failure of standard therapy with platinum-containing preparations.
As adjuvant treatment paclitaxel is indicated in treatment of node-positive breast carcinoma after anthracycline and cyclophosphamide (AC) treatment. Adjuvant treatment with paclitaxel should be considered as an alternative to prolonged AC treatment.
Paclitaxel is indicated as initial treatment of locally advanced or metastatic breast carcinoma either in combination with anthracycline in patients in whom anthracycline treatment is suitable or in combination with trastuzumab, in patients who over-express HER-2 at a level of 3+ as determined by immunohistochemistry methods and to patients in whom anthracycline treatment is not suitable (see sections 4.4 and 5.1).
Paclitaxel is indicated as a single agent for treatment of metastatic breast carcinoma in patients in whom standard anthracycline therapy has failed or in whom anthracycline therapy is not suitable.
Advanced non-small-cell lung carcinoma
Paclitaxel, in combination with cisplatin, is indicated for treatment of non-small-cell lung carcinoma (NSCLC) in patients who are not candidates for potentially curative surgery and/or radiotherapy.
AIDS-related Kaposi’s sarcoma
Paclitaxel is indicated for the treatment of patients with advanced AIDS-related Kaposi´s sarcoma (KS) who have failed prior liposomal anthracycline therapy.
Solution for injection 15mg/5ml, 30mg/10ml, 60mg/20ml, 90mg/30ml
Treatment of conditions associated with increased osteoclast activity:
Capsules 5mg, 20mg, 100mg, 140mg, 180mg, 250mg
Temomedac (temozolomide) capsules is indicated for the treatment of:
Solution for infusion 1mg/1ml, 4mg/4ml
Topotecan monotherapy is indicated for the treatment of: